Clinical Algorithm For the Follow-Up of Aortic Valve Disease

The incidence of valvular aortic stenosis (AS) is estimated to be 0.2-0.4 per 1,000 live births. Bicuspid aortic valve (BAV) is the most common cause of AS and one of the most common types of congenital heart disease, with an incidence estimated by autopsy studies of approximately 1%.

Rotterdam Study: 3-Decade Decline in Total and Unrecognized MI

Rates of total and unrecognized myocardial infarction (MI) have decreased from the 1990s to the 2010s, according to an analysis of the Rotterdam Study published recently in JAMA Cardiology. Nevertheless, Julie Anne Eni van Oortmerssen, MD, MSc, et al., maintain the importance of continued efforts to identify unrecognized MI.

Emerging Evidence: Refractory Angina and Coronary Sinus Reducers

Refractory angina (RA) is an increasing global cardiovascular challenge, affecting approximately 10-15% of patients with coronary artery disease (CAD). RA is defined as persistent anginal symptoms (≥3 months) due to myocardial ischemia despite guideline-directed medical therapy…

ENCIRCLE MAC Registry: One-Year TMVR Outcomes

Transseptal transcatheter mitral valve replacement (TMVR) with the SAPIEN M3 system among patients with symptomatic mitral annular calcification (MAC)-related mitral valve dysfunction (MVD) was associated with sustained mitral regurgitation (MR) reduction and improved symptoms and quality of life at one year…

AMUNDSEN: Does Early Evolocumab Improve Outcomes in Acute MI?

Lipid lowering after acute myocardial infarction (MI) is central to secondary prevention, but stepwise therapy may delay LDL-C target attainment. The AMUNDSEN trial, presented at ESC Congress 2026 and simultaneously published in JAMA, assessed whether pre-PCI evolocumab could accelerate LDL-C reduction and improve clinical outcomes.

Arrhythmia-Related Trials Featured at ESC Congress 2026: Implications on Clinical Practice

ESC Congress 2026 featured several arrhythmia-related clinical trials. SINGLE-AF investigated anticoagulation in patients with atrial fibrillation (AFib) and intermediate stroke risk, PVI-SHAM-AF compared whether catheter ablation improves AFib-related quality of life more than a sham procedure, ASPIRED tested 14-day ECG monitoring in patients with unexplained syncope…